ClinicalTrials.gg
CompletedNCT00161681Updated Feb 8, 2013

Study Evaluating Levonorgestrel/Ethinyl Estradiol (LNG/EE) in PMS

A Phase 3 interventional study of Levonorgestrel/Ethinyl Estradiol in Premenstrual Syndrome, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 48 sites in United States. Open to female participants aged 18 Years to 49 Years. Per ClinicalTrials.gov, last updated 2013-02-08.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies in Premenstrual Syndrome with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Premenstrual Syndrome · United States.

Enrollment
4th of 31
200 · median 40
Started
2005
with 1 other
Phase 3
3 of 36
none open now
Registered
9th of 36
by date
Lead sponsor
2 of 36
Wyeth is now a wholly owned subsidiary of Pfizer

Among the 36 studies in Premenstrual Syndrome with a site in United States, this one is the 4th largest by enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2005, is one of 3 in phase 3, and was the 9th registered.

Premenstrual Syndrome

177 studies on the registry are indexed under Premenstrual Syndrome; 32 are open to participants now.

Browse Premenstrual Syndrome studies →

Open to participants now

6 of the 36 studies in Premenstrual Syndrome with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Premenstrual Syndrome studies recruiting now, none (0%) set no upper age limit and 12 (100%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.

This study: 18 Years to 49 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Premenstrual Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether LNG/EE is effective in the treatment of menstrual cycle related symptoms.

03

Conditions studied

  • Premenstrual Syndrome

Browse trials for

Keywords

  • Levonorgestrel
  • ethinyl estradiol
  • premenstrual syndrome
  • menstrual cycle related symptoms
04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy women aged 18 to 49 years
  • Regular 21 to 35 day menstrual cycles for 3 months prior to study visit 1
  • History of menstrual cycle related symptoms as determined by the investigator.

Exclusion criteria

Exclusion Criteria:

  • to combination oral
  • Depression requiring hospitalization or associated with suicidal ideation within the last 3 years
  • Use of antidepressants/anxiolytics within 10 days of screening and for the duration of the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
200 participants

Interventions

06

What researchers measure

Primary outcomes

  1. To evaluate the efficacy of a continuous-use OC regimen containing a combination of LNG/EE in preventing moderate to severe cycle-related symptoms compared with placebo

Secondary outcomes

  1. To evaluate the effects of this LNG/EE regimen on work productivity and subject satisfaction in subjects with moderate to severe cycle-related symptoms at baseline compared with placebo

07

Study locations

48 sites
  • Huntsville, Alabama 35801, United States
  • Peoria, Arizona 85381, United States
  • Phoenix, Arizona 85031, United States
  • Phoenix, Arizona 85032, United States
  • Tucson, Arizona 85715, United States
  • San Diego, California 92103, United States
  • Denver, Colorado 80202, United States
  • Longmont, Colorado 80501, United States
  • Aventura, Florida 33180, United States
  • Boynton Beach, Florida 33437, United States
  • Clearwater, Florida 33761, United States
  • Deland, Florida 32720, United States
  • Fort Myers, Florida 33916, United States
  • Miami, Florida 33143, United States
  • Miami, Florida 33186, United States
  • Pembroke Pines, Florida 33024, United States
  • Tampa, Florida 33607, United States
  • West Palm Beach, Florida 33407, United States
  • Atlanta, Georgia 30328, United States
  • Atlanta, Georgia 30342, United States
  • Savannah, Georgia 31406, United States
  • Idaho Falls, Idaho 83404, United States
  • Chicago, Illinois 60612, United States
  • Chicago, Illinois 60631, United States
  • Lexington, Kentucky 40509, United States
  • Kansas City, Missouri 64114, United States
  • Las Vegas, Nevada 89109, United States
  • Las Vegas, Nevada 89118, United States
  • Moorestown, New Jersey 08057, United States
  • Rochester, New York 14609, United States
  • Fayetteville, North Carolina 28304, United States
  • Winston-Salem, North Carolina 27103, United States
  • Cleveland, Ohio 44122, United States
  • Mogadore, Ohio 44260, United States
  • Eugene, Oregon 97401, United States
  • Medford, Oregon 97504, United States
  • Philadelphia, Pennsylvania 19104, United States
  • Pittsburgh, Pennsylvania 15206, United States
  • Wexford, Pennsylvania 15090, United States
  • Hilton Head Island, South Carolina 29926, United States
  • Mt. Pleasant, South Carolina 29464, United States
  • Nashville, Tennessee 37203, United States
  • Houston, Texas 77024, United States
  • San Antonio, Texas 78229, United States
  • Sandy, Utah 84070, United States
  • Richmond, Virginia 23226, United States
  • Lakewood, Washington 98499, United States
  • Seattle, Washington 98105, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2005, a primary completion of Aug 2006 and a completion of Aug 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2005
First posted
Sep 12, 2005
Start
Jul 2005
Primary completionActual
Aug 2006
CompletionActual
Aug 2006
Last update
Feb 8, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00161681
Responsible party
Sponsor
First posted
Sep 12, 2005
Start date
Jul 2005
Primary completion
Aug 2006
Completion
Aug 2006
Last update
Feb 8, 2013

Study contacts

Medical Monitor, MD
study director · Wyeth is now a wholly owned subsidiary of Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Levonorgestrel · Ethinyl Estradiol

Start the discussion